Navigation Links
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Date:6/15/2009

differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
3. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
4. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
5. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
6. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
7. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
8. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
9. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
10. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
11. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... The Board of,Directors of Shire plc (LSE: SHP, ... announces today that David Mott will,join the Board ... Mr Mott is Chief Executive Officer and ... to in 2000. He joined MedImmune in 1992 ...
... ... Data, VANCOUVER ... a clinical-stage developer of drugs for infectious,diseases will present at the Acumen ... York Palace Hotel in New York,NY on November 5-7, 2007. Jim DeMesa, ...
... Oct. 31 Amedica Corporation,an orthopedic implants company ... the U.S. Food and Drug Administration,has granted 510(k) ... The Valeo(TM) Cervical Plate system combines features aimed ... The,Valeo(TM) Cervical Plate system is intended for anterior ...
Cached Biology Technology:David Mott Appointed Non Executive Director at Shire 2David Mott Appointed Non Executive Director at Shire 3MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... of the world, rice is one of the most important plants ... part, the task of a group of three researchers from Iowa ... are looking at two bacterial diseases of rice. The most costly ... called Xanthomonas oryzae pathovar oryzae , and can diminish yield ...
... is increasingly undervalued in conflicts over reproductive rights, including ... a new study by a University of Illinois legal ... recent reproductive rights cases shows that judges may shortchange ... interests, such as religious freedom, potentially leading to rulings ...
... by the dazzling displays of green light often seen ... at Scripps Institution of Oceanography at UC San Diego ... produce the green glow and the biological mechanisms behind ... attract suitors in an undersea mating ritual. Research conducted ...
Cached Biology News:Researchers examine bacterial rice diseases, search for genetic solutions 2Study: Health undervalued in reproductive rights debate 2Scripps scientists help decode mysterious green glow of the sea 2
... This volume provides excellent background information, ... study of major HIV proteins including: the ... integrase and protease. Expression of HIV proteins ... Rev assays; HIV/CD4 interactions; transient assays for ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Tachykinin (H-2)...
Biology Products: